Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.

An evaluation of potential antibody formation to biologic therapeutics during the course of nonclinical safety studies and its impact on the toxicity profile is expected under current regulatory guidance and is accepted standard practice. However, approaches for incorporating this information in the interpretation of nonclinical safety studies are not clearly established. Described here are the immunological basis of anti-drug antibody formation to biopharmaceuticals (immunogenicity) in laboratory animals, and approaches for generating and interpreting immunogenicity data from nonclinical safety studies of biotechnology-derived therapeutics to support their progression to clinical evaluation. We subscribe that immunogenicity testing strategies should be adapted to the specific needs of each therapeutic development program, and data generated from such analyses should be integrated with available clinical and anatomic pathology, pharmacokinetic, and pharmacodynamic data to properly interpret nonclinical studies.

[1]  D. Wierda.  Animal Models for Preclinical Comparative Immunogenicity Testing , 2008 .

[2]  J. Arnout,et al.  Factor VIII Inhibitors in Previously Treated Haemophilia A Patients with a Double Virus-inactivated Plasma Derived Factor VIII Concentrate , 1997, Thrombosis and Haemostasis.

[3]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[4]  N V Katre,et al.  Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. , 1990, Journal of immunology.

[5]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[6]  D. Vignali,et al.  How regulatory T cells work , 2008, Nature Reviews Immunology.

[7]  M. Nussenzweig,et al.  Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.

[8]  M. Streiff,et al.  Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure , 2002, Transfusion.

[9]  J. Rossert.  Erythropoietin‐induced, antibody‐mediated pure red cell aplasia * , 2005, European journal of clinical investigation.

[10]  S. Strobel,et al.  Immune responses to dietary antigens: oral tolerance. , 1998, Immunology today.

[11]  D. Scott,et al.  Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". , 2008, Blood.

[12]  Leonard Moise,et al.  Prediction of immunogenicity for therapeutic proteins: state of the art. , 2007, Current opinion in drug discovery & development.

[13]  Patrick Mayeux,et al.  Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.

[14]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[15]  A. Badger,et al.  Preclinical development of keliximab, a Primatized™ anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies , 2000, Human & experimental toxicology.

[16]  M. Biffoni,et al.  Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. , 1997, Cytokines, cellular & molecular therapy.

[17]  L. Klein,et al.  Origin of regulatory T cells with known specificity for antigen , 2002, Nature Immunology.

[18]  J. Astermark.  Basic aspects of inhibitors to factors VIII and IX and the influence of non‐genetic risk factors , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  S. Jameson,et al.  Central tolerance: learning self-control in the thymus , 2005, Nature Reviews Immunology.

[20]  Hendrik Neubert,et al.  Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry. , 2008, Analytical chemistry.

[21]  Kai-Uwe Eckardt,et al.  Epoetin-induced autoimmune pure red cell aplasia. , 2005, Journal of the American Society of Nephrology : JASN.

[22]  G. Avgerinos,et al.  Production and clinical development of a Hansenula polymorpha-derived PEGylated hirudin. , 2001, Seminars in thrombosis and hemostasis.

[23]  R. Steinman,et al.  The Induction of Tolerance by Dendritic Cells That Have Captured Apoptotic Cells , 2000, The Journal of experimental medicine.

[24]  H. Doyle,et al.  Post-translational protein modifications in antigen recognition and autoimmunity. , 2001, Trends in immunology.

[25]  P. Bugelski,et al.  Immunopharmacology of recombinant human interleukin-18 in non-human primates. , 2002, Cytokine.

[26]  M. Urowitz,et al.  CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. , 1995, Arthritis and rheumatism.

[27]  S. Pestka,et al.  Interferon immunogenicity: preclinical evaluation of interferon-alpha 2a. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[28]  A. Sette,et al.  Isoaspartyl Post-translational Modification Triggers Autoimmune Responses to Self-proteins* , 1999, The Journal of Biological Chemistry.

[29]  Mark C Evans,et al.  Recent advances in immunoinformatics: application of in silico tools to drug development. , 2008, Current opinion in drug discovery & development.

[30]  Ying Tang,et al.  Monoclonal Antibody Clearance , 2007, Journal of Biological Chemistry.

[31]  A. Agulnik,et al.  The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. , 1997, Immunity.

[32]  Francesco M Veronese,et al.  PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.

[33]  H. Weiner,et al.  Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. , 1994, Science.

[34]  S. Belknap,et al.  Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. , 2005, Blood.

[35]  P. Shaw,et al.  Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. , 1999, Life sciences.

[36]  Viswanath Devanarayan,et al.  Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.

[37]  D. Dresser.  Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen. , 1962, Immunology.

[38]  G. Woods,et al.  Neonatal exposure to UV‐B radiation leads to a large reduction in Langerhans cell density, but by maturity, there is an enhanced ability of dendritic cells to stimulate T cells , 2006, Immunology and cell biology.

[39]  Marian Kelley,et al.  Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. , 2007, Journal of immunological methods.

[40]  Julie McMurry,et al.  Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. , 2008, Current opinion in pharmacology.

[41]  Allen Schantz,et al.  Immunogenicity of therapeutic monoclonal antibodies. , 2003, Current opinion in molecular therapeutics.

[42]  Steven J. Swanson,et al.  Evaluation of Methods to Detect and Characterize Antibodies against Recombinant Human Erythropoietin , 2004, Nephron Clinical Practice.

[43]  C. Kurts,et al.  Brief Definitive Report Major Histocompatibility Complex Class I–restricted Cross-presentation Is Biased towards High Dose Antigens and Those Released during Cellular Destruction , 2022 .

[44]  H. Weiner,et al.  Peripheral deletion of antigen-reactive T cells in oral tolerance , 1995, Nature.

[45]  Gopi Shankar,et al.  A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs , 2007, Nature Biotechnology.

[46]  H. Weiner,et al.  Activation of CD25+CD4+ Regulatory T Cells by Oral Antigen Administration1 , 2001, The Journal of Immunology.

[47]  P. Matzinger,et al.  B cells turn off virgin but not memory T cells. , 1992, Science.

[48]  C. Kurts,et al.  Cutting Edge: Dendritic Cells Are Sufficient to Cross-Present Self-Antigens to CD8 T Cells In Vivo1 , 2001, The Journal of Immunology.

[49]  P. Delamater.  Growth disorders: The state of the art Edited by Luciano Cavallo, Jean Claude Job, and Maria 1. New. Serono Symposia Publications, volume 81., New York, Raven, 1991, $110.50 (xv + 372 pages), ISBN 0-881-67786-8 , 1992, Trends in Endocrinology & Metabolism.

[50]  James D. Green,et al.  Comparative Pathology of Recombinant Murine Interferon-γ in Mice and Recombinant Human Interferon-γ in Cynomolgus Monkeys , 1993 .

[51]  H. Gunn.  Immunogenicity of recombinant human interleukin-3. , 1997, Clinical immunology and immunopathology.

[52]  K. Shokat,et al.  Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Rajat Varma,et al.  Peptide-MHC potency governs dynamic interactions between T cells and dendritic cells in lymph nodes , 2007, Nature Immunology.

[54]  B. Arnold.  Levels of peripheral T cell tolerance. , 2002, Transplant immunology.

[55]  Huub Schellekens,et al.  Factors influencing the immunogenicity of therapeutic proteins. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[56]  R. D. Hatton,et al.  Regulatory T Cell Suppression and Anergy Are Differentially Regulated by Proinflammatory Cytokines Produced by TLR-Activated Dendritic Cells1 , 2004, The Journal of Immunology.

[57]  A. Faiella,et al.  The rhGM-CSF-EPO hybrid protein MEN 11300 induces anti-EPO antibodies and severe anaemia in rhesus monkeys. , 1998, Cytokine.

[58]  J. Vielmetter,et al.  Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. , 2006, Clinical immunology.

[59]  Bruce N. Rehlaender,et al.  Antibodies as Carrier Proteins , 1998, Pharmaceutical Research.

[60]  D. Kuter.  The use of PEG‐rHuMGDF in platelet apheresis , 1998, Stem cells.

[61]  Application of analytical detection concepts to immunogenicity testing. , 2007, Analytical chemistry.

[62]  C. Maury,et al.  Induction of tolerance to recombinant therapeutic proteins. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[63]  T. Elliott,et al.  Glycan-regulated Antigen Processing of a Protein in the Endoplasmic Reticulum Can Uncover Cryptic Cytotoxic T Cell Epitopes , 1998, The Journal of experimental medicine.

[64]  D. Parker,et al.  Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. , 1992 .

[65]  N. Fineberg,et al.  Immunologic Effects of Insulin Lispro [Lys (B28), Pro (B29) Human Insulin] in IDDM and NIDDM Patients Previously Treated With Insulin , 1996, Diabetes.

[66]  Viswanath Devanarayan,et al.  Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. , 2008, Journal of immunological methods.

[67]  P. Bugelski,et al.  Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. , 2004, Current opinion in molecular therapeutics.

[68]  U. V. von Andrian,et al.  Single-cell dynamics of T-cell priming. , 2007, Current opinion in immunology.

[69]  R. Medzhitov,et al.  Toll-like receptors: balancing host resistance with immune tolerance. , 2003, Current opinion in immunology.

[70]  R. Daynes,et al.  The effects of high-dose UV exposure on murine Langerhans cell function at exposed and unexposed sites as assessed using in vivo and in vitro assays. , 1983, The Journal of investigative dermatology.

[71]  Basant Sharma,et al.  Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes. , 2007, Biotechnology advances.

[72]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[73]  A. Khoruts,et al.  The anatomy of T-cell activation and tolerance. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[74]  M. Hershfield,et al.  Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase , 2005, Arthritis research & therapy.

[75]  H. Weiner,et al.  Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[76]  R. Smalling,et al.  Granulocyte colony stimulating factor: animal studies for risk assessment. , 1993, International review of experimental pathology.

[77]  H. Smith,et al.  Immunogenicity of biopharmaceuticals in laboratory animals. , 2001, Toxicology.

[78]  A. Jaber,et al.  Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. , 2007, Journal of pharmaceutical and biomedical analysis.

[79]  G. Shankar,et al.  Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. , 2005, Journal of pharmaceutical and biomedical analysis.

[80]  J. Griffin,et al.  Altered humoral immunity during pregnancy in the guinea pig. , 1987, Journal of reproductive immunology.

[81]  M. Lotze,et al.  High-Dose Recombinant Interleukin-18 Induces an Effective Th1 Immune Response to Murine MOPC-315 Plasmacytoma , 2002, Journal of immunotherapy.

[82]  Hong Zhao,et al.  Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. , 2006, Bioconjugate chemistry.

[83]  A. Pilaro,et al.  Safety Assessment of Biotechnology-Derived Pharmaceuticals: ICH and Beyond , 1999, Toxicologic pathology.

[84]  P. Bugelski,et al.  Identification of natural antibodies to interleukin-18 in the sera of normal humans and three nonhuman primate species. , 2003, Clinical immunology.

[85]  L. Fugger,et al.  Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease , 1998, Nature Medicine.

[86]  B. Segal,et al.  Activation of APCs Through CD40 or Toll-Like Receptor 9 Overcomes Tolerance and Precipitates Autoimmune Disease1 , 2002, The Journal of Immunology.

[87]  Karina Yusim,et al.  Immunoinformatics Comes of Age , 2006, PLoS Comput. Biol..

[88]  Erika Giste,et al.  Preclinical safety of recombinant human thrombin. , 2007, Regulatory toxicology and pharmacology : RTP.

[89]  J. Egrie,et al.  Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. , 1998, Journal of the American Veterinary Medical Association.

[90]  D. Dale,et al.  Chronic thrombocytopenia is induced in dogs by development of cross-reacting antibodies to the MpL ligand. , 1997, Blood.

[91]  A. Valdés,et al.  The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4+ T-cell epitope in human interferon-β , 2004, Genes and Immunity.

[92]  V. Tomassini,et al.  Neutralizing and Binding Antibodies to IFN-β: Relative Frequency in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different IFN-β Preparations , 2002 .

[93]  J. Lawson.  The clinical use and immunologic impact of thrombin in surgery. , 2006, Seminars in thrombosis and hemostasis.

[94]  P. Bugelski,et al.  Preclinical Safety of Recombinant Human Interleukin-18 , 2003, Toxicologic pathology.

[95]  C. Yang,et al.  Thrombocytopenia caused by the development of antibodies to thrombopoietin. , 2001, Blood.

[96]  R. Aston,et al.  Antibody-mediated enhancement of hormone activity. , 1989, Molecular immunology.

[97]  R. Morgan,et al.  Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[98]  G. Gregoriadis,et al.  Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. , 2005, International journal of pharmaceutics.

[99]  F. Legay,et al.  Improvement of drug tolerance in immunogenicity testing by acid treatment on Biacore. , 2008, Journal of immunological methods.

[100]  R. Heine,et al.  Efficacy and safety of inhaled insulin in the treatment of diabetes mellitus. , 2006, The Netherlands journal of medicine.

[101]  Gopi Shankar,et al.  Scientific and regulatory considerations on the immunogenicity of biologics. , 2006, Trends in biotechnology.

[102]  A. Enk,et al.  Immature, but not inactive: the tolerogenic function of immature dendritic cells , 2002, Immunology and cell biology.

[103]  D. Masterman,et al.  Development of a Maturing T-Cell-Mediated Immune Response in Patients with Idiopathic Parkinson’s Disease Receiving r-metHuGDNF Via Continuous Intraputaminal Infusion , 2007, Journal of Clinical Immunology.

[104]  R. Dwek,et al.  Glycosylation and the immune system. , 2001, Science.

[105]  Darren R Flower,et al.  Immunoinformatics and the prediction of immunogenicity. , 2002, Applied bioinformatics.

[106]  A. Mire-Sluis,et al.  Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. , 2002, Current pharmaceutical biotechnology.

[107]  R. Ponce,et al.  Toxicity as a result of immunostimulation by biologics , 2007, Expert opinion on drug metabolism & toxicology.

[108]  H. Heiken,et al.  The IgG Fc receptor family , 1998, Annals of Hematology.

[109]  Jochem Alsenz,et al.  Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic Mice , 1997, Pharmaceutical Research.

[110]  P. Gallo,et al.  Interferon-beta (IFN-β) antibodies in interferon-β1a-and interferon-β1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo , 2001 .

[111]  L. Shultz,et al.  Constant rate of steady-state self-antigen trafficking from skin to regional lymph nodes. , 2006, International immunology.

[112]  M. Mihm,et al.  Characterization of Langerhans cells by the use of monoclonal antibodies. , 1981, Laboratory investigation; a journal of technical methods and pathology.

[113]  A. Khoruts,et al.  Studying Immunological Tolerance by Physically Monitoring Antigen‐specific T Cells in Vivo a , 1996, Annals of the New York Academy of Sciences.

[114]  M. Wadhwa,et al.  Unwanted Immunogenicity: Implications for Follow-on Biologicals , 2007 .

[115]  Anthony Mire-Sluis,et al.  Characterizing biological products and assessing comparability following manufacturing changes , 2004, Nature Biotechnology.

[116]  T. Boone,et al.  Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.

[117]  E. A. Graham.  The Influence of Ether and Ether Anesthesia on Bacteriolysis, Agglutination, and Phagocytosis , 1911 .

[118]  C. Orosz,et al.  Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. , 1991, Journal of immunology.

[119]  Division on Earth.  Guide for the Care and Use of Laboratory Animals , 1996 .

[120]  G. Giovannoni,et al.  The Rebif® New Formulation Story , 2007, Drugs in R&D.

[121]  L. Old,et al.  Pharmacokinetics and microdistribution of polyethylene glycol‐modified humanized A33 antibody targeting colon cancer xenografts , 2000, International journal of cancer.

[122]  T. Hamilton,et al.  UV exposure reduces immunization rates and promotes tolerance to epicutaneous antigens in humans: relationship to dose, CD1a-DR+ epidermal macrophage induction, and Langerhans cell depletion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[123]  W. Heath,et al.  Cross-presentation, dendritic cells, tolerance and immunity. , 2001, Annual review of immunology.

[124]  E. Harlow,et al.  Antibodies: A Laboratory Manual , 1988 .

[125]  C. Goodnow,et al.  The need for central and peripheral tolerance in the B cell repertoire. , 1990, Science.

[126]  H. G. Wells.  Studies on the Chemistry of Anaphylaxis (III). Experiments with Isolated Proteins, Especially those of the Hen's Egg , 1911 .